HVHA Medical
Develops biomedical materials (hydrogels, colloidal silver, bacterial cellulose) and bio-3D printing inks for surgical hemostasis, sealing, anti-adhesion, and tissue regeneration.
- CEO / Founder
- Feng Yongliang
- Team Size
- 201-500
- Stage
- Growth Stage
- Latest Round
- Series B
- Key Investors
- Jiangsu Runhuai Industrial Development Fund
Technology & Products
Key Products
Hemostatic agents; Surgical sealants; Anti-adhesion barriers; Soft tissue management products; Bio-3D printing inks; Bacterial cellulose dressings; Colloidal silver products; Hydrogel products
Technological Advantage
Proprietary biomaterial formulations and a bio-3D printing platform focused on tissue regeneration; protected by over 50 medical device registrations (including 2 Class III devices) and 5 products recognized as innovative by Chinese regulatory authorities, creating regulatory and IP barriers.
Differentiation
Value Proposition
Provides a comprehensive portfolio of high-performance, clinically validated biomaterials and bio-inks that enable advanced tissue engineering and regenerative medicine applications, supported by over 50 medical device registrations.
How They Differentiate
Offers a vertically integrated portfolio from raw biomaterials to bio-3D printing inks, with a strong focus on the Chinese regulatory landscape and local manufacturing, unlike global giants that may not have specialized bio-3D ink production.
Market & Competition
Target Customers
Hospitals, surgeons, medical distributors, and patients requiring advanced wound care and tissue repair solutions.
Industry Verticals
Medical Devices; Healthcare; Regenerative Medicine; Tissue Engineering
Competitors
3M Health Care; Integra LifeSciences; Smith & Nephew
Growth & Milestones
Growth Metrics
Holds over 50 medical device registration certificates, including 5 recognized as innovative medical devices.
Major Milestones
Founded (2005/2009); Strategic investment (June 2017); Awarded Jiangsu Province 'Specialized, Refined, Differential, and New' designation (2024/2025); Series B funding (August 2025)
Notable Customers
CPAC Environmental Solutions